HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Blame The ‘Hamsters’: Germany’s Paediatric Fever Medicine Shortage Worsens

Executive Summary

An ongoing crisis in the availability of children's fever medicines in Germany is due to stockpiling – or “hamstering” – by pharmacists and wholesalers, says the country's medicines regulator. This is disputed by not just pharmacists and wholesalers, but also manufacturers, which blame Germany's fixed price system for reimbursable medicines, which includes OTC children's fever medicines. Nevertheless, the German government is seeking to address the real causes of the crisis with a new draft generics law, which is being welcomed by industry. 

You may also be interested in...



OTC Shortages Top Of Mind For North American, European and Asia Pacific Consumers

An overwhelming majority of consumers surveyed by IT consultancy Capgemini are concerned they will not be able to obtain the OTC health products they require or want. In the event of shortages – which are currently affecting consumers across Europe – many respondents said they would substitute with another brand, or in some cases not purchase at all.

German Generic Reform To Relax Pediatric Pricing

Germany’s Bundesministerium für Gesundheit is reworking the country’s off-patent drug legislation to allow for more flexible pricing.

International Trade Groups Call For Regulators To Protect Off-Patent Industry From Inflation

Rising inflation has exacerbated pressures in the off-patent drug sector, prompting Medicines for Europe and the US Association for Accessible Medicines to call for regulatory intervention to ensure the long-term sustainability of the space.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153226

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel